Overview
Type: Synthetic peptide
Form: Lyophilized powder
CRF2/CRHR2 (extracellular) Blocking Peptide (#BLP-CR052) is the original antigen used for immunization during Anti-CRF2/CRHR2 (extracellular) Antibody (#ACR-052) generation. The blocking peptide binds and ‘blocks’ Anti-CRF2/CRHR2 (extracellular) primary antibody, this makes it a good negative reagent control to help confirm antibody specificity in western blot and immunohistochemistry applications. This control is also often called a pre-adsorption control.
Applications: wb, ihc
For research purposes only. not for human use
Applications
Demonstration of Pre-adsorption control
Western blot analysis of mouse brain membrane (lanes 1 and 5), rat cerebellum (lanes 2 and 6), rat lung (lanes 3 and 7) and rat kidney (lanes 4 and 8) lysates:1-4. Anti-CRF2/CRHR2 (extracellular) Antibody (#ACR-052), (1:200).
5-8. Anti-CRF2/CRHR2 (extracellular) Antibody, preincubated with CRF2/CRHR2 (extracellular) Blocking Peptide (#BLP-CR052).
Western blot analysis of human MOLT-4 acute lymphoblastic leukemia (lanes 1 and 5), human CAKI-1 renal cell carcinoma (lanes 2 and 6), human MEG-O1 megakaryoblastic leukemia (lanes 3 and 7) and human COLO-205 colon adenocarcinoma (lanes 4 and 8) cell line lysates:1-4. Anti-CRF2/CRHR2 (extracellular) Antibody (#ACR-052), (1:200).
5-8. Anti-CRF2/CRHR2 (extracellular) Antibody, preincubated with CRF2/CRHR2 (extracellular) Blocking Peptide (#BLP-CR052).
Properties
Sequence
- (C)EELLLDGWGEPPDPE, corresponding to amino acid residues 20-34 of rat CRHR2 (Accession P47866).
Accession (Uniprot) Number P47866
Peptide Confirmation Confirmed by amino acid analysis and mass spectrometry.
Purity >70%
Storage Before Reconstitution Lyophilized powder can be stored intact at room temperature for two weeks. For longer periods, it should be stored at -20°C.
Reconstitution 100 µl double distilled water (DDW).
Storage After Reconstitution -20°C.
Antigen Preadsorption Control 1 µg peptide per 1 µg antibody.
Standard Quality Control Of Each Lot Western blot analysis.
